Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 77.5%

Neg 77.5% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $47 to $45.